Syndax Pharmaceuticals
SNDX
72 hedge funds and large institutions have $128M invested in Syndax Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 26 increasing their positions, 14 reducing their positions, and 8 closing their positions.
86% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 14
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
12% more call options, than puts
Call options by funds: $3.39M | Put options by funds: $3.02M
1% more funds holding
Funds holding: 71 → 72 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.21% less ownership
Funds ownership: 63.37% → 63.16% (-0.21%)
20% less capital invested
Capital invested by funds: $160M → $128M (-$31.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
+$3.64M |
| 2 |
State Street
Boston,
Massachusetts
|
+$829K |
| 3 |
Renaissance Technologies
New York
|
+$593K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$507K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$457K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
-$4.05M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$2.05M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.64M |
| 4 |
USAA
United Services Automobile Association
San Antonio,
Texas
|
-$1.15M |
| 5 |
CCIA
Campbell & Co Investment Adviser
Baltimore,
Maryland
|
-$367K |
SNDX Hedge Fund Activity: Q3 2019 in Review
72 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q3 2019, worth a combined $128M — down 20% from $160M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new SNDX positions and 8 closed out — a net gain of 1 holder — while 26 added to existing stakes and 14 trimmed.
The largest buyer was Boxer Capital, opening a new position worth an estimated $3.64M. The largest seller was 683 Capital Management, cutting an estimated $4.05M.
- 72 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q3 2019, up from 71 in Q2 2019.
- Funds reported $128M of Syndax Pharmaceuticals stock for Q3 2019, down 20% quarter-over-quarter.
- 9 funds opened new Syndax Pharmaceuticals positions in Q3 2019 and 8 closed out, a net change of +1 holder.
- The largest Syndax Pharmaceuticals buyer in Q3 2019 was Boxer Capital, an estimated $3.64M added.
- The largest Syndax Pharmaceuticals seller in Q3 2019 was 683 Capital Management, an estimated $4.05M sold.
Based on aggregated 13F filings for Q3 2019.